PURE - PURE Bioscience (NASDAQ:PURE)

[alumnum]

info

Pure Bioscience, Inc. engages in the discovery, development, and commercialization of bioscience products principally in the United States. The company offers silver dihydrogen citrate (SDC) based antimicrobials. The silver dihydrogen citrate technology is an electrochemical process that allows the generation of ionized silver in the presence of organic acid. It provides PURE Hard Surface, a hard surface disinfectant and food contact surface sanitizer for use in food processing equipment, machinery, and utensils; Axen30, a hard surface disinfectant; Silvérion, an antimicrobial formulation used as a raw material in the manufacturing of personal care products; and Axenohl, an antimicrobial formulation for use as a raw material in the manufacturing of environmental protection agency-registered products. The company also offers research and development services in food processing, agriculture, water treatment, pharmaceuticals, and oil and gas projects. It sells its products through partners and distributors primarily to industrial and consumer markets. The company, formerly known as Innovative Medical Services, was founded in 1992 and is headquartered in El Cajon, California.

Revenue (ttm): 929.18K
Revenue Per Share (ttm): 0.18
Qtrly Revenue Growth (yoy): 61.70%
Gross Profit (ttm): 332.79K
EBITDA (ttm)6: -7.99M
Net Income Avl to Common (ttm): -8.41M
Diluted EPS (ttm): -1.59
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 289.00K
Total Cash Per Share (mrq): 0.05
Total Debt (mrq): 0.00
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 0.80
Book Value Per Share (mrq): 0.30
Cash Flow Statement
Operating Cash Flow (ttm): -5.51M
Levered Free Cash Flow (ttm): -2.97M
View Financials
Income Statement - Balance Sheet - Cash Flow

Trading Information
Stock Price History
Beta: 1.05
52-Week Change3: -78.71%
S&P500 52-Week Change3: 20.57%
52-Week High (Oct 17, 2011)3: 6.00
52-Week Low (Sep 26, 2012)3: 0.90
50-Day Moving Average3: 1.73
200-Day Moving Average3: 2.45
Share Statistics
Avg Vol (3 month)3: 200,929
Avg Vol (10 day)3: 188,843
Shares Outstanding5: 6.26M
Float: 6.05M
% Held by Insiders1: 3.23%
% Held by Institutions1: 2.60%
Shares Short (as of Sep 14, 2012)3: 368.92K
Short Ratio (as of Sep 14, 2012)3: 1.50
Short % of Float (as of Sep 14, 2012)3: 5.70%
Shares Short (prior month)3: 98.24K

 

[alumnum]

Feedback cercasi

Ieri il titolo in questione ha messo a segno 10 punti percentuali nell'ultima mezz'ora.....da una prima analisi non sembra malvagio ....qualcuno la conosce o segue da più tempo?

 

[alumnum]

pre agitata

...vedremo se oggi confermerà il trend o meno....se qualcuno ha cortesemente un grafico.....buon trade a tutti

 

[Roman66]

...vedremo se oggi confermerà il trend o meno....se qualcuno ha cortesemente un grafico.....buon trade a tutti

Ha chiuso un gap e per ora può arrivare sotto la trend a 1,55-1,60.
Ma come ti ho già detto è un titolo tossico anche se vende saponette

 

[alumnum]

Ha chiuso un gap e per ora può arrivare sotto la trend a 1,55-1,60.
Ma come ti ho già detto è un titolo tossico anche se vende saponette

sarà anche una saponetta, ma lo spike l'ha fatto

 

[coffeman]

Pure

up da seguire

 

[Roman66]

up da seguire

Ottimo tempismo

 

[coffeman]

occhio a AEZS e OCLS .

 

[microciop]

Ottimo tempismo

Sempre il solito maledetto vizio di andare a ravanare sulle croste



Form 8-K for PURE BIOSCIENCE, INC.


--------------------------------------------------------------------------------

26-Dec-2012

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand



Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On December 20, 2012, Pure Bioscience, Inc. (the "Company"), received a deficiency letter (the "Notification Letter") from The NASDAQ Stock Market ("NASDAQ") notifying the Company that it no longer meets NASDAQ's requirements for continued listing on the NASDAQ Capital Market under NASDAQ Listing Rule 5550(a)(2) (the "Bid Price Rule") because the minimum bid price of the Company's common stock has not equaled or exceeded $1.00 at least once over a period of 30 consecutive business days. The Notification Letter does not impact the Company's listing on the NASDAQ Capital Market at this time and the Company's common stock will continue to trade on the NASDAQ Capital Market under the symbol "PURE."

NASDAQ explained in the Notification Letter that under NASDAQ Listing Rule 5810(c)(3)(A), the Company will be afforded 180 calendar days, or until June 18, 2013, to regain compliance with the Bid Price Rule. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for at least 10 consecutive business days during that 180-day period. If the Company does not regain compliance by June 18, 2013, then NASDAQ will provide written notification to the Company that the Company's common stock will be subject to delisting from the NASDAQ Capital Market. The Company may, however, be eligible for an additional grace period of 180 calendar days if it satisfies the continued listing requirement for market value of publicly held shares and all other initial listing standards (with the exception of the Bid Price Rule) for listing on the NASDAQ Capital Market, and submits a timely notification to NASDAQ of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. The Company may also appeal NASDAQ's delisting determination to a NASDAQ Hearings Panel.

The Company intends to actively monitor the bid price of its common stock and will consider available options to resolve the deficiency and regain compliance with NASDAQ requirements. Such actions could include implementation of a reverse split of the Company's common stock, which would need to be authorized by the Company's stockholders, or other possible actions. The Company has not yet determined what action or actions it may pursue to regain compliance with NASDAQ's continued listing requirements, and there can be no assurance that the Company will be able to regain compliance with NASDAQ's continued listing requirements.

 

[microciop]

occhio a AEZS e OCLS .

Non mescolare orazi e curiazi

AEZS è solo per i traders di lungo corso

 

[coffeman]

Sempre il solito maledetto vizio di andare a ravanare sulle croste



Form 8-K for PURE BIOSCIENCE, INC.


--------------------------------------------------------------------------------

26-Dec-2012

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand



Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On December 20, 2012, Pure Bioscience, Inc. (the "Company"), received a deficiency letter (the "Notification Letter") from The NASDAQ Stock Market ("NASDAQ") notifying the Company that it no longer meets NASDAQ's requirements for continued listing on the NASDAQ Capital Market under NASDAQ Listing Rule 5550(a)(2) (the "Bid Price Rule") because the minimum bid price of the Company's common stock has not equaled or exceeded $1.00 at least once over a period of 30 consecutive business days. The Notification Letter does not impact the Company's listing on the NASDAQ Capital Market at this time and the Company's common stock will continue to trade on the NASDAQ Capital Market under the symbol "PURE."

NASDAQ explained in the Notification Letter that under NASDAQ Listing Rule 5810(c)(3)(A), the Company will be afforded 180 calendar days, or until June 18, 2013, to regain compliance with the Bid Price Rule. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for at least 10 consecutive business days during that 180-day period. If the Company does not regain compliance by June 18, 2013, then NASDAQ will provide written notification to the Company that the Company's common stock will be subject to delisting from the NASDAQ Capital Market. The Company may, however, be eligible for an additional grace period of 180 calendar days if it satisfies the continued listing requirement for market value of publicly held shares and all other initial listing standards (with the exception of the Bid Price Rule) for listing on the NASDAQ Capital Market, and submits a timely notification to NASDAQ of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. The Company may also appeal NASDAQ's delisting determination to a NASDAQ Hearings Panel.

The Company intends to actively monitor the bid price of its common stock and will consider available options to resolve the deficiency and regain compliance with NASDAQ requirements. Such actions could include implementation of a reverse split of the Company's common stock, which would need to be authorized by the Company's stockholders, or other possible actions. The Company has not yet determined what action or actions it may pursue to regain compliance with NASDAQ's continued listing requirements, and there can be no assurance that the Company will be able to regain compliance with NASDAQ's continued listing requirements.

dici che è sempre **** trovare quelle che salgono??
il delisting è rimandato a giugno svegliaaaaa.
claudiano è il 100simo nick che cambi

 

[microciop]

dici che è sempre **** trovare quelle che salgono??
il delisting è rimandato a giugno svegliaaaaa.
claudiano è il 100simo nick che cambi

Dovuto a ripetuteBannato

 

[microciop]

dici che è sempre **** trovare quelle che salgono??
il delisting è rimandato a giugno svegliaaaaa.

Non ha neanche gli occhi per piangere

PURE Income Statement | PURE Bioscience, Inc. Stock - Yahoo! Finance

 

[coffeman]

non avrà neanche gli occhi per piangere ma ieri in apertura nei primi 5 minuti ha toccato quota 1,24 cioè + 35 % per poi ritracciare ma lo spyke previsto lo ha fatto ed è questo che conta impara come funziona claudiano il colpo d'occhio fà la differenza

 

[visal]

non avrà neanche gli occhi per piangere ma ieri in apertura nei primi 5 minuti ha toccato quota 1,24 cioè + 35 % per poi ritracciare ma lo spyke previsto lo ha fatto ed è questo che conta impara come funziona claudiano il colpo d'occhio fà la differenza

Io sono dentro da ieri bello carico

 

[visal]

RAga comprate tutti il loro disinfettante su ordinate dal sito facciamo risalire le quotazioni
Go go go